Compare iShares MSCI China ETF (MCHI) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Novavax Inc — how do they compare? iShares MSCI China ETF trades at $53.9, while Novavax Inc trades at $8.12 (market cap $1.30B). The key difference: Novavax Inc is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| MCHI | NVAX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $66.99 | $11.19 |
52-Week Low | $50.48 | $6.22 |
Market Cap | — | $1.30B |
Enterprise Value | — | $800.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $54.08, up 2.13% with a bullish technical signal from moving averages. The stock shows neutral momentum oscillators with RSI at 68.39 suggesting mild overbought conditions. Recent news highlights China's focus on AI infrastructure investment and export controls on technology sectors, creating both opportunities and regulatory uncertainties for China-focused ETFs.
The outlook remains cautiously optimistic given China's economic stabilization efforts and AI sector growth, though geopolitical tensions and value trap concerns present significant risks. Wall Street sentiment appears mixed with some analysts highlighting structural headwinds while others see potential in the technology sector rebound.
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
